Expansion of Genedata's Collaboration with Serono into High Content Screening
Genedata announced the expansion of its screening analysis collaboration with Serono. Scientists at Serono now use Genedata's computational solution to combine results from high content screening assays with chemical and pharmacological information as part of the process to identify promising candidates for drug development.
High content data from cellular assay technologies used at Serono enable sophisticated biological profiling. These screening technologies provide insights into the biological effects of potential drug candidates, including possible toxic side effects. To exploit these technologies, screening results need to be shared among people with different expertise, including chemists and toxicologists.
During the course of the collaboration, Genedata extended its Screener® result management and analysis solution, enabling Seronos researchers to analyze and annotate their screening results more efficiently. The collaboration quickly reached the point where the software was a precise fit with Seronos needs, according to the company.
Other news from the department business & finance
These products might interest you
Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management
LAUDA.LIVE by LAUDA
LAUDA.LIVE - The digital platform for your device management
Comprehensive fleet management options for every LAUDA device - with and without IoT connectivity
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
